UnknownPhase 2

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

53 participantsStarted 2022-04-30

Plain-language summary

Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- HLA A2 Positive PDL1 Positive Treatment naive, triple negative breast cancer Exclusion Criteria: \-

What they're measuring

Progression Free Survival

Timeframe: 8 months

Trial details

NCT IDNCT04634747

SponsorOncoPep, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-04-01

View on ClinicalTrials.gov More Metastatic Triple-Negative Breast Carcinoma trials